Condition
Neuroendocrine Tumor of the Lung
Total Trials
4
Recruiting
1
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (2)
P 1 (1)
P 2 (1)
Trial Status
Not Yet Recruiting2
Recruiting1
Active Not Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06941480Phase 1Not Yet RecruitingPrimary
A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate
NCT06148636Early Phase 1Active Not Recruiting
A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors
NCT05557708Early Phase 1Not Yet Recruiting
A Safety Study of 212Pb-Pentixather Radioligand Therapy
NCT06472388Phase 2Recruiting
Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine Tumors
Showing all 4 trials